CD8A and cancer: For example, a recent study characterized diverse genetic alterations in MIBC that convergently lead to constitutive activation of PPARγ/RXRα and result in immunosurveillance escape by inhibiting CD8+ T-cell recruitment [15].Thus, the outcome of PPARγ agonists use might be variable in different circumstances of tumorigenesis including cancer types and disease stages.